Website use cookies to track the number of visitors. We use the Google Analytics tool. We also use Twitter cookies for Twitter timeline.

Better access
Better health

Medicines manufacturing in the Czech Republic

Current Time 0:00
Duration Time 0:00
Progress: NaN%
kinds of medicinal products
million delivered packages every year
10 out of 20
top-selling generics
years on the Czech market

What they said about us

Prof. Mudr. Vlastimil Válek CSc., MBA, EBIRHealth minister

Generic and biosimilar drugs reduce health care costs and thanks to that, treatment is accessible to more patients who need it and can access it in an earlier stage of a disease.

Ing. Zdeněk KabátekDirector of VZP

We view generic drugs and biosimilars as very important for the securing of health care sustainability and the budget stability of health insurance companies. Generics and biosimilars allow us to increase the number of treated patients and provide better treatment accessibility.

Mgr. Irena Starová, MHADirector of SÚKL

Sadly, the number of chronically ill patients is increasing. However, thanks to our activity in the area of generics and biosimilars, treatment is accessible to a higher number of patients, and we manage to stabilize the expenses.

Our members